Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kv3.1 and Kv3.2 are voltage-gated potassium channels encoded by the KCNC1 and KCNC2 genes, respectively, belonging to the Shaw-related (Kv3) subfamily [1, 5]. They are uniquely characterized by high activation thresholds and exceptionally fast activation and deactivation kinetics, which are essential for the rapid repolarization of action potentials [1, 16]. This allows specific neuronal populations, such as parvalbumin-positive GABAergic interneurons and auditory brainstem neurons, to sustain high-frequency firing rates up to 1000 Hz [1, 14]. In the central nervous system, these channels play a pivotal role in regulating neuronal excitability and synchronizing network activity, including the generation of gamma oscillations [8, 12]. Mutations or reduced expression of Kv3.1/3.2 are associated with a range of neurological and psychiatric conditions, including progressive myoclonus epilepsy, schizophrenia, and age-related hearing loss [1, 6, 13]. Pharmacological targeting of these channels primarily involves positive allosteric modulators (PAMs), such as AUT00206 and AUT00063, which aim to restore the firing capacity of inhibitory interneurons and correct excitatory-inhibitory imbalances [2, 8, 20].
Positive allosteric modulation (PAM) of Kv3.1 and Kv3.2 channels, which shifts the voltage-dependence of activation to more negative potentials and increases the firing frequency of fast-spiking neurons.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 1 and 2 (Kv3.1/Kv3.2).